Our findings, together with the results of clinical reports [24, 25, 43], strongly suggest that inhibition of IDO activity might lead to the development of new treatments for chronic liver disease as well as strategies to prevent HCC. The gene discussed is IDO1; the disease is hepatocellular carcinoma.